Liposomal Amphotericin B, and Not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae
AS Ibrahim, V Avanessian, B Spellberg… - Antimicrobial agents …, 2003 - Am Soc Microbiol
AS Ibrahim, V Avanessian, B Spellberg, JE Edwards Jr
Antimicrobial agents and chemotherapy, 2003•Am Soc MicrobiolThe efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB)
were compared in a diabetic murine model of hematogenously disseminated Rhizopus
oryzae infection. At 7.5 mg/kg of body weight twice a day (bid), LAmB significantly improved
overall survival compared to the rates of survival in both untreated control mice (P= 0.001)
and mice treated with 0.5 mg of AmB per kg bid (P= 0.047). These data indicate that high-
dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.
were compared in a diabetic murine model of hematogenously disseminated Rhizopus
oryzae infection. At 7.5 mg/kg of body weight twice a day (bid), LAmB significantly improved
overall survival compared to the rates of survival in both untreated control mice (P= 0.001)
and mice treated with 0.5 mg of AmB per kg bid (P= 0.047). These data indicate that high-
dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.
Abstract
The efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB) were compared in a diabetic murine model of hematogenously disseminated Rhizopus oryzae infection. At 7.5 mg/kg of body weight twice a day (b.i.d.), LAmB significantly improved overall survival compared to the rates of survival in both untreated control mice (P = 0.001) and mice treated with 0.5 mg of AmB per kg b.i.d. (P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.
American Society for Microbiology